Medical Device Startup Costs Keep Running After Clearance Into Distribution and Adoption

Published
November 18, 2026
Last updated
November 10, 2026
Table of contents

Medical device startup costs have no single number. They start with clinical and regulatory choices, move through manufacturing and keep running after clearance into adoption.

Mako Surgical's founding board member recalls raising about $150 million to reach $100 million in sales, though published funding estimates vary.

You budget for the trial and the FDA submission. Clearance arrives. Then the money meant for the trial is gone and the market hasn't moved.

Key Takeaways

  • Mako Surgical's founding board member Chris Dewey recalls the company raising about $150 million to reach $100 million in sales, though published funding estimates vary.
  • Features Capital's partners say founders spend too much on clinical and regulatory strategy, and that trial costs have exploded.
  • The same partners say manufacturing, quality systems and supply chain belong in early planning to speed time to market.
  • MedTech Innovator founder Paul Grand calls the period right after regulatory approval a valley of death, because teams had just enough money and evidence to get there.
  • I've said that distribution and scaling adoption cost a lot in medtech, even when the trial doesn't.
  • The Features Capital partners said their check size runs from $500,000 to $2 million, so early rounds have to be planned carefully.

Watch the Full Episode on YouTube

What Are the Biggest Medical Device Startup Costs?

Brass balance scale tipping toward a tall stack of glass discs over a single small glass sphere.

Clinical and regulatory strategy is often the first big cost, and the choices you make early decide how large it gets. Features Capital's partners say founders spend too much here, because the cost of running a trial has risen sharply.

I interviewed Jenny Barba and Jeff Chu, co-founders of Features Capital in Norwich, Vermont, on an episode about founder conviction, clinical adoption and capital efficiency. On the episode, they described how they help founders get ready for the next round. One of the partners said:

"Clinical regulatory strategies is where we spend too much money on."

I asked them to expand on that. They pointed to the cost of trials.

"The cost of clinical trials today have exploded, right?"

Their advice is to treat the FDA and CMS as a negotiation. Understand their key risks and how they operate, then build something that satisfies them. That can mean reducing the size of a trial, simplifying it, or pushing back on a primary endpoint.

The point is that trial design is a cost decision, not just a science decision. For how that decision connects to the rest of the plan, see how a business plan for a medical device startup fails when it ends at regulatory clearance.

When Should You Plan Manufacturing and Quality System Costs?

Glass and steel assembly line with one stage glowing amber on a dark reflective floor.

Plan manufacturing, quality systems and supply chain before you need them. The Features Capital partners said an early engineer often says "we'll get to manufacturing," and that thinking about it earlier gets the product to market faster.

The same conversation covered the sales side. They said a team that doesn't understand how to sell into its channel is in trouble, and they described the bottom-up analysis they want founders to do. Who pays? What is the competition doing?

How will the data package support a commercial launch?

Clinical study design, site selection and the clinical advisory board all affect the commercial win later. Manufacturing choices affect speed to market.

I'd put all of them in one view before you raise. When an investor asks what the money buys, you want to answer with one plan.

Do Medical Device Startup Costs Stop After FDA Clearance?

Glass staircase rising into hazy blue light with only the first few steps lit.

No. After clearance, the largest costs are often distribution and scaling adoption. Mako Surgical shows how large they get. Its founding board member recalls about $150 million raised by the time the company reached $100 million in sales.

I interviewed Chris Dewey, a founding board member at Mako, on an episode about fundraising in medtech. I'd said that it costs money to take a medical device to market, and I asked about surgical robotics. Dewey said:

"With Mako, we must have raised 50 million bucks, something like that, before we went public, and then we raised another 100 million after we were public."

He then gave the result.

"It cost us 150 million bucks to get to 100 million in sales at the time."

Dewey said the amount would be higher today, and that he could give examples of companies raising more right now. He was working from memory, and published estimates of Mako's total funding vary, so treat his numbers as a recollection.

Mako's annual report for 2012 shows revenue of about $102.7 million. Mako was a surgical robotics company, so I wouldn't use it as a benchmark for every device.

I'd use it as a reminder that the build and the market are two separate bills.

I made the same point on an episode about the month's medtech news. In 2025, I said that in our industry it doesn't cost a lot of money to go through clinical trials compared with biotech, but it costs a lot to develop and distribute.

That view sits beside the Features Capital view that trials have gotten expensive. Both can be true. Trials are costly, and adoption is the cost that keeps running.

For more on getting product into the channel, read how distribution strategy for medical device companies fails when capital runs short.

What Is the Valley of Death After Regulatory Approval?

The valley of death is the period right after approval, and it's the riskiest point for your budget. Paul Grand, who founded MedTech Innovator, says many companies reach approval with just enough money and evidence to get there, and then the market asks for more.

I interviewed Grand on an episode about avoiding the biggest startup mistakes. Grand described a valley of death made up of companies that got regulatory approval with just enough money and evidence to get there.

Grand also said the bar for what makes a company interesting keeps moving. Approval alone used to be a milestone that added value. Now most companies realize they need revenue traction too.

So the budget question changes. The budget question becomes how much it costs to reach the traction that the next investor or acquirer wants to see.

What Do Medical Device Startup Costs Mean for Medtech Founders?

It means you should budget in three layers, the build, the approval and the adoption, and raise for the third as seriously as the first. Companies that plan only for clearance have to raise again at a weaker point.

I'd say adoption is the cost that gets underestimated. Clinical validation isn't commercial traction, and FDA clearance is the starting line, not the finish line. The money after clearance has to buy proof that the market will move.

Market engineering helps here. At MarketCraft, we build the market narrative before launch, so the spend after clearance goes toward a market that already understands why you matter. Great companies don't wait for markets to form. They engineer them.

Before your next raise, list your clinical and regulatory costs and test how a smaller trial design would change them. Put manufacturing and quality systems in the same plan.

Then estimate what it costs to reach the traction an investor wants to see, and compare your raise against that full picture.

For more on the funding side, see how medical device startup funding closes faster when category work happens first and how medical device startup valuation starts with the number you plan to raise.

On The State of MedTech, the founders who raise well can explain what each dollar buys.

Frequently Asked Questions

How much does it cost to start a medical device company?

There's no single number, because it depends on the device, the trial and the market. The cost has three parts, development, approval and adoption.

For scale, Mako Surgical's founding board member Chris Dewey recalls about $150 million raised by the time it reached $100 million in sales. That was a surgical robotics company, published estimates vary, and Dewey said costs run higher today.

What is the biggest cost after FDA clearance?

Distribution and scaling adoption. I've said it costs a lot to develop, distribute and scale adoption, even when the trial itself doesn't cost much.

Paul Grand adds that many companies reach approval with just enough money and evidence, then face a valley of death.

Why are clinical trials so expensive for startups?

The Features Capital partners say the cost of executing a trial has exploded. They advise founders to treat regulators as a negotiation.

Ways to reduce cost include shrinking the trial, reducing its complexity or pushing back on a primary endpoint.

How much do early investors write for a medtech startup?

It varies by firm. The Features Capital partners said their check size runs from $500,000 to $2 million, depending on where they are in their portfolio model.

They're often the first institutional check, so they help companies prepare for the next round with governance, sales channel analysis and team building.

How Do You Get Started Planning Medical Device Startup Costs?

If you're doing this yourself. Build the three-layer budget above, then use the medtech commercialization strategy guide to cost the adoption layer. Listen to The State of MedTech for founders' funding stories.

If you want it engineered with you. MarketCraft takes on a small number of medtech teams each quarter, starting with The Market Engineering Audit. We'd check whether your post-clearance plan buys the traction your next investor wants.

Listen to the Full Conversations

These episodes of The State of MedTech informed this post.

Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry. He works with medtech founders and commercial leaders on market engineering, commercialisation strategy, and revenue growth.

Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.

Copied!